Kessoku, Takaomi

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 153

Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease

Imajo, K., Honda, Y., Kobayashi, T., Nagai, K., Ozaki, A., Iwaki, M., Kessoku, T., Ogawa, Y., Takahashi, H., Saigusa, Y., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 140

Non‐alcoholic fatty liver disease comorbid with major depressive disorder: the pathological features and poor therapeutic efficacy

Tomeno, W., Kawashima, K., Yoneda, M., Saito, S., Ogawa, Y., Honda, Y., Kessoku, T., Imajo, K., Mawatari, H., Fujita, K., et al. (2015) · Journal of Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 98

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2025) · Diabetes mellitus

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 1